BiotechTube
Slam BioTherapeutics

Slam BioTherapeutics

Cambridge, United States· Est.
slambio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SLAM BioTherapeutics is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA. The company is developing a proprietary platform of anti-CD84 (SLAMF5) ADCs and bispecifics for hematologic cancers, with a lead asset, SLM124, on track for an IND filing in early 2026 and clinical trial initiation in the second half of 2026. Backed by over $10M in seed funding and led by a seasoned team with a track record of successful exits, SLAM Bio plans a $30M+ Series A round in Q3 2025 to fund initial clinical trials and pipeline expansion.

OncologyHematology

Technology Platform

Platform of first-in-class humanized monoclonal antibodies targeting the SLAMF5 (CD84) receptor, engineered into Antibody-Drug Conjugates (ADCs) and bispecific antibodies for hematologic cancers.

Opportunities

The first-in-class targeting of CD84 addresses a significant unmet need in aggressive blood cancers like AML and MDS, representing a large and growing market.
Success in the clinic could position the company as an attractive partner or acquisition target for larger pharma companies active in oncology and ADC space.

Risk Factors

High scientific risk as the novel CD84 target is unproven in humans; preclinical efficacy may not translate to clinical trials.
The company is reliant on securing a $30M+ Series A round in Q3 2025 to fund clinical entry, introducing financing and execution risk.

Competitive Landscape

The competitive landscape is intense, with numerous companies developing ADCs and bispecifics for hematologic malignancies, including large pharma and well-funded biotechs. SLAM Bio's differentiation hinges on the novelty of the CD84 target, but it must demonstrate superior efficacy or safety to compete against established and emerging therapies.

More companies in Biologics / Biosimilars →More companies in United States →